Antibodies Assay Kits Bap1 Antibody Biology Cells Brd4 Antibody Canine Albumin cDNA Culture Cells Devices Glut2 Antibody Gsk3 Alpha Hama Antibodies Medium & Serums Muc2 Antibody NATtrol Nedd4 Antibody Nox1 Antibody PCR Reagents Recombinant Proteins Ria Kits RNA Tgf Alpha Elisa Vector & Virus Vi Alpha Vitronectin Antibody Western Blot Zebrafish Antibodies
Human-SARS-CoV-2 interactome and human genetic diversity: TMPRSS2-rs2070788, associated with severe influenza, and its population genetics caveats in Native Americans
For human/SARS-CoV-2 interactome genes ACE2, TMPRSS2 and BSG, there’s a convincing proof of affiliation in Asians with influenza-induced SARS for TMPRSS2-rs2070788, tag-SNP of the eQTL rs383510. This case illustrates the significance of inhabitants genetics and of sequencing knowledge within the design of genetic affiliation research in several human populations: the excessive linkage disequilibrium (LD) between rs2070788 and rs383510 is Asian-specific.
Leveraging on a mixture of genotyping and sequencing knowledge for Native Individuals (uncared for in genetic research), we present that whereas their frequencies of the Asian tag-SNP rs2070788 is, surprisingly, the best worldwide, it isn’t in LD with the eQTL rs383510, that subsequently, must be straight genotyped in genetic affiliation research of SARS in populations with Native American ancestry.
PRICKLE1 × FOCAD Interplay Revealed by Genome-Broad vQTL Evaluation of Human Facial Traits
The human face is a extremely advanced and variable construction ensuing from the intricate coordination of quite a few genetic and non-genetic elements. A whole bunch of genomic loci impacting quantitative facial options have been recognized.
Whereas these associations have been proven to affect morphology by altering the imply dimension and form of facial measures, their impact on trait variance stays unclear. We carried out a genome-wide affiliation evaluation for the variance of 20 quantitative facial measurements in 2,447 European people and recognized a number of suggestive variance quantitative trait loci (vQTLs).
These vQTLs guided us to conduct an environment friendly seek for gene-by-gene (G × G) interactions, which uncovered an interplay between PRICKLE1 and FOCAD affecting cranial base width. We replicated this G × G interplay sign on the locus stage in an extra 5,128 Korean people.
We used the hypomorphic Prickle1 Beetlejuice (Prickle1 Bj ) mouse line to straight take a look at the perform of Prickle1 on the cranial base and noticed wider cranial bases in Prickle1 Bj/Bj . Importantly, we noticed that the Prickle1 and Focadhesin proteins co-localize in murine cranial base chondrocytes, and this co-localization is irregular within the Prickle1 Bj/Bj mutants.
Taken collectively, our findings uncovered a novel G × G interplay impact in people with robust help from each epidemiological and molecular research. These outcomes spotlight the potential of finding out measures of phenotypic variability in gene mapping research of facial morphology.
Proof for opposing selective forces working on human-specific duplicated TCAF genes in Neanderthals and people
TRP channel-associated issue half (TCAF1/TCAF2) proteins antagonistically regulate the cold-sensor protein TRPM8 in a number of human tissues. Understanding their significance has been difficult given the locus spans a gap-ridden area with advanced segmental duplications in GRCh38. Utilizing long-read sequencing, we sequence-resolve the locus, annotate full-length TCAF fashions in primate genomes, and present substantial human-specific TCAF copy quantity variation.
We determine two human tremendous haplogroups, H4 and H5, and set up that TCAF duplications originated ~1.7 million years in the past however diversified solely in Homo sapiens by recurrent structural mutations. Conversely, in all archaic-hominin samples the fixation for a particular H4 haplotype with out duplication is probably going on account of constructive choice.
Right here, our outcomes of TCAF copy quantity enlargement, choice alerts in hominins, and differential TCAF2 expression between haplogroups and excessive TCAF2 and TRPM8 expression in liver and prostate in modern-day people suggest TCAF diversification amongst hominins doubtlessly in response to chilly or dietary diversifications.
A world map of associations between varieties of protein posttranslational modifications and human genetic ailments
There are >200 varieties of protein posttranslational modifications (PTMs) described in eukaryotes, every with distinctive proteome protection and capabilities. We hypothesized that some genetic ailments could also be attributable to the removing of a particular kind of PTMs by genomic variants and the resultant deregulation of explicit capabilities.
We collected >320,000 human PTMs representing 59 varieties and crossed them with >4M nonsynonymous DNA variants annotated with predicted pathogenicity and illness associations. We report >1.74M PTM-variant co-occurrences that an enrichment evaluation distributed into 215 pairwise associations between 18 PTM varieties and 148 genetic ailments.
Of them, 42% weren’t beforehand described. Elimination of lysine acetylation exerts probably the most pronounced impact, and fewer studied PTM varieties equivalent to S-glutathionylation or S-nitrosylation present relevance. Utilizing pathogenicity predictions, we recognized PTM websites that will produce explicit ailments if prevented. Our outcomes present proof of a considerable affect of PTM-specific removing on the pathogenesis of genetic ailments and phenotypes.
Human Codon Utilization: The Genetic Foundation of Pathogen Latency
Infectious ailments pose two important compelling points. First, the identification of the molecular elements that enable continual infections, that’s, the customarily fully asymptomatic coexistence of infectious brokers with the human host. Second, the definition of the mechanisms that enable the swap from pathogen dormancy to pathologic (re)activation.
Furthering earlier research, the current examine (1) analyzed the frequency of prevalence of synonymous codons in coding DNA, that’s, codon utilization, as a genetic device that guidelines protein expression; (2) described how human codon utilization can inhibit protein expression of infectious brokers throughout latency, in order that pathogen genes the codon utilization of which doesn’t conform to the human codon utilization can’t be translated; and (3) framed human codon utilization among the many front-line devices of the innate immunity towards infections.
In parallel, it was proven that, whereas genetics can account for the molecular foundation of pathogen latency, the modifications of the quantitative relationship between codon frequencies and isoaccepting tRNAs throughout cell proliferation supply a biochemical mechanism that explains the pathogen switching to (re)activation. Immunologically, this examine warns that utilizing codon optimization methodologies can (re)activate, potentiate, and immortalize in any other case quiescent, asymptomatic pathogens, thus resulting in uncontrollable pandemics.
Engineered human induced pluripotent cells allow genetic code enlargement in mind organoids
Human induced pluripotent stem cell (hiPSC) expertise has revolutionized human biology. A variety of cell varieties and tissue fashions will be derived from hiPSCs to review advanced human ailments. Right here, we use PiggyBac mediated transgenesis to engineer hiPSCs with an expanded genetic code. We reveal that genomic integration of expression cassettes for a pyrrolysyl-tRNA synthetase (PylRS), pyrrolysyl-tRNA (PylT) and the goal protein of curiosity permits site-specific incorporation of a non-canonical amino acid (ncAA) in response to amber cease codons.
West Nile Virus Envelope Protein |
|||
abx060680-50g | Abbexa | 50 µg | Ask for price |
West Nile Virus Envelope Antibody |
|||
24282 | SAB | 100ul | EUR 479 |
West Nile Virus Envelope Antibody |
|||
24282-100ul | SAB | 100ul | EUR 468 |
West Nile Virus Envelope Antibody |
|||
24283 | SAB | 100ul | EUR 479 |
West Nile Virus Envelope Antibody |
|||
24283-100ul | SAB | 100ul | EUR 468 |
West Nile Virus Envelope Antibody |
|||
24284 | SAB | 100ul | EUR 479 |
West Nile Virus Envelope Antibody |
|||
24284-100ul | SAB | 100ul | EUR 468 |
West Nile Virus Envelope Antibody |
|||
3437-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
West Nile Virus Envelope Antibody |
|||
3437-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
West Nile Virus Envelope Antibody |
|||
3439-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
West Nile Virus Envelope Antibody |
|||
3439-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
West Nile Virus Envelope Antibody |
|||
3441-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
West Nile Virus Envelope Antibody |
|||
3441-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
West Nile Virus Envelope Recombinant |
|||
rAP-5504 | Angio Proteomie | Inquiry | Ask for price |
West Nile Envelope Virus Protein |
|||
20-abx260322 | Abbexa |
|
|
West Nile Envelope Virus Protein |
|||
abx260322-10g | Abbexa | 10 µg | EUR 950 |
West Nile Envelope Virus Protein |
|||
abx260322-2g | Abbexa | 2 µg | EUR 350 |
West Nile Virus Envelope Protein Antibody |
|||
abx022312-1mg | Abbexa | 1 mg | EUR 1296 |
West Nile Virus Envelope Protein Antibody |
|||
abx022314-1mg | Abbexa | 1 mg | EUR 1228.8 |
West Nile Virus Envelope Protein Antibody |
|||
abx022315-1mg | Abbexa | 1 mg | EUR 1296 |
West Nile Virus Envelope Protein Antibody |
|||
abx022316-1mg | Abbexa | 1 mg | EUR 1296 |
West Nile Virus Envelope Protein Antibody |
|||
abx022312-400l | Abbexa | 400 µl | Ask for price |
West Nile Virus Envelope Protein Antibody |
|||
abx022312-80l | Abbexa | 80 µl | EUR 1250 |
West Nile Virus Envelope Protein Antibody |
|||
abx022314-400l | Abbexa | 400 µl | Ask for price |
West Nile Virus Envelope Protein Antibody |
|||
abx022314-80l | Abbexa | 80 µl | EUR 1362.5 |
West Nile Virus Envelope Protein Antibody |
|||
abx022315-400l | Abbexa | 400 µl | Ask for price |
West Nile Virus Envelope Protein Antibody |
|||
abx022315-80l | Abbexa | 80 µl | EUR 1250 |
West Nile Virus Envelope Protein Antibody |
|||
abx022316-400l | Abbexa | 400 µl | Ask for price |
West Nile Virus Envelope Protein Antibody |
|||
abx022316-80l | Abbexa | 80 µl | EUR 1250 |
West Nile Envelope Virus (Recombinant) |
|||
22060756-1 | Glycomatrix | 100 µg | EUR 264.47 |
Recombinant West Nile Envelope Virus |
|||
7-07960 | CHI Scientific | 100µg | Ask for price |
Recombinant West Nile Envelope Virus |
|||
7-07961 | CHI Scientific | 500µg | Ask for price |
Recombinant West Nile Envelope Virus |
|||
7-07962 | CHI Scientific | 1000µg | Ask for price |
West Nile Virus Envelope recombinant antigen |
|||
00401-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: West Nile Virus Envelope recombinant antigen-Immunodominant region |
West Nile Virus Envelope recombinant antigen |
|||
00401-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: West Nile Virus Envelope recombinant antigen-Immunodominant region |
West Nile Virus Envelope Recombinant Protein |
|||
53-361 | ProSci | 0.01 mg | EUR 714.3 |
Description: West Nile Virus Envelope Recombinant Protein |
Polyclonal West Nile Virus Envelope Antibody |
|||
AMM05448G | Leading Biology | 0.1 mg | EUR 790.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human West Nile Virus Envelope . This antibody is tested and proven to work in the following applications: |
Polyclonal West Nile Virus Envelope Antibody |
|||
AMM05449G | Leading Biology | 0.1 mg | EUR 790.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human West Nile Virus Envelope . This antibody is tested and proven to work in the following applications: |
Polyclonal West Nile Virus Envelope Antibody |
|||
APR11226G | Leading Biology | 0.1 mg | EUR 790.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human West Nile Virus Envelope . This antibody is tested and proven to work in the following applications: |
West Nile Virus Envelope recombinant antigen |
|||
8822 | Virostat | 100 ug | EUR 529.8 |
Description: This is West Nile Virus Envelope recombinant antigen for ELISA,WB. |
Recombinant West Nile Virus Envelope Protein |
|||
P1065-10 | Biovision | each | EUR 189.6 |
Recombinant West Nile Virus Envelope Protein |
|||
P1065-50 | Biovision | each | EUR 366 |
West Nile Virus Envelope (WNV E) Antibody |
|||
abx201395-100l | Abbexa | 100 µl | EUR 450 |
West Nile Virus Envelope (WNV E) Antibody |
|||
abx201395-50l | Abbexa | 50 µl | EUR 312.5 |
West Nile Virus Envelope (WNV E) Antibody |
|||
abx201396-100l | Abbexa | 100 µl | EUR 450 |
West Nile Virus Envelope (WNV E) Antibody |
|||
abx201396-50l | Abbexa | 50 µl | EUR 312.5 |
West Nile Virus Envelope Protein ELISA Kit |
|||
VPK-5154 | Cell Biolabs | 96 assays | EUR 660 |
Mouse antibody for West Nile Virus Envelope |
|||
3655 | Virostat | 100 ug | EUR 386.26 |
Description: This is purified Mouse monoclonal antibody against West Nile Virus Envelope for WB, ELISA. |
Mouse antibody for West Nile Virus Envelope |
|||
3661 | Virostat | 100 ug | EUR 386.26 |
Description: This is purified Mouse monoclonal antibody against West Nile Virus Envelope for WB, ELISA. |
Mouse antibody for West Nile Virus Envelope |
|||
3671 | Virostat | 100 ug | EUR 386.26 |
Description: This is purified Mouse monoclonal antibody against West Nile Virus Envelope for WB, ELISA. |
West Nile Virus EnvelopeHis |
|||
PR-1275 | Jena Bioscience GmbH | 100µg | EUR 300.7 |
Description: recombinant, E. coli |
OPNB00039-100UG - West Nile Virus - Envelope protein |
|||
OPNB00039-100UG | Aviva Systems Biology | 100ug | EUR 658 |
OPNB00039-500UG - West Nile Virus - Envelope protein |
|||
OPNB00039-500UG | Aviva Systems Biology | 500ug | EUR 2656 |
West Nile Virus Envelope Domain III (WNV ED3) Antibody |
|||
abx201397-100l | Abbexa | 100 µl | EUR 450 |
West Nile Virus Envelope Domain III (WNV ED3) Antibody |
|||
abx201397-50l | Abbexa | 50 µl | EUR 312.5 |
West Nile Virus Envelope Domain III (WNV ED3) Antibody |
|||
abx201398-100l | Abbexa | 100 µl | EUR 450 |
West Nile Virus Envelope Domain III (WNV ED3) Antibody |
|||
abx201398-50l | Abbexa | 50 µl | EUR 312.5 |
West Nile Virus Envelope Domain III (WNV ED3) Antibody |
|||
abx201399-100l | Abbexa | 100 µl | EUR 450 |
West Nile Virus Envelope Domain III (WNV ED3) Antibody |
|||
abx201399-50l | Abbexa | 50 µl | EUR 312.5 |
OAGA07998-100UL - West Nile virus Envelope protein Antibody |
|||
OAGA07998-100UL | Aviva Systems Biology | 100ul | EUR 369 |
OAGA08675-100UL - West Nile virus Envelope protein Antibody |
|||
OAGA08675-100UL | Aviva Systems Biology | 100ul | EUR 369 |
West Nile Virus Envelope Recombinant Protein 6-his liquid |
|||
IWNVWNVENVR6HIS10UG | Innovative research | each | EUR 851 |
Description: West Nile Virus Envelope Recombinant Protein 6-his liquid |
West Nile Virus Envelope recombinant antigen-Immunodominant region |
|||
00401-V | Virogen | 1 MG | EUR 850 |
West Nile Virus Envelope recombinant antigen-Immunodominant region |
|||
00401-V-100ugvial | Virogen | 100 ug/vial | EUR 150 |
Description: West Nile Virus Envelope recombinant antigen-Immunodominant region |
Recombinant West Nile Virus Envelope Protein (N-terminus), His-tagged |
|||
DAG566 | Creative Diagnostics | 100ug | EUR 786 |
Recombinant West Nile Virus WNV Envelope Protein, His, E.coli-1mg |
|||
QP13964-1mg | EnQuireBio | 1mg | EUR 1513.2 |
Recombinant West Nile Virus WNV Envelope Protein, His, E.coli-100ug |
|||
QP13964-100ug | EnQuireBio | 100ug | EUR 261.6 |
Recombinant West Nile Virus WNV Envelope Protein, His, E.coli-500ug |
|||
QP13964-500ug | EnQuireBio | 500ug | EUR 795.6 |
West Nile Virus Envelope full length recombinant antigen 42 kDa region |
|||
00403-V | Virogen | 1 MG | EUR 850 |
West Nile Virus Envelope full length recombinant antigen 42 kDa region |
|||
00403-V-100ugvial | Virogen | 100 ug/vial | EUR 150 |
Description: West Nile Virus Envelope full length recombinant antigen 42 kDa region |
West Nile Virus Envelope Protein mouse monoclonal antibody, clone B857M, Purified |
|||
AM31657PU-N | Origene Technologies GmbH | 1 mg | Ask for price |
West Nile Virus Envelope Protein mouse monoclonal antibody, clone B851M, Purified |
|||
AM31658PU-N | Origene Technologies GmbH | 1 mg | Ask for price |
West Nile Virus Envelope Protein mouse monoclonal antibody, clone B849M, Purified |
|||
AM31659PU-N | Origene Technologies GmbH | 1 mg | Ask for price |
West Nile Virus Envelope Protein mouse monoclonal antibody, clone B847M, Purified |
|||
AM31661PU-N | Origene Technologies GmbH | 1 mg | Ask for price |
Rabbit Polyclonal Anti-West Nile Virus Envelope Antibody |
|||
TA160067 | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit Polyclonal Anti-West Nile Virus Envelope Antibody |
|||
TA160068 | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit Polyclonal Anti-West Nile Virus Envelope Antibody |
|||
TA160069 | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit Anti-West Nile Virus Envelope Protein Antibody (9E2) |
|||
MAB12297-100 | The Native Antigen Company | 0.1 | EUR 825.42 |
Description: Rabbit polyclonal antibody specific for West Nile virus Envelope (clone 9E2) |
Rabbit Anti-West Nile Virus Envelope Protein Antibody (9E2) |
|||
MAB12297-200 | The Native Antigen Company | 0.2 | EUR 1224.72 |
Description: Rabbit polyclonal antibody specific for West Nile virus Envelope (clone 9E2) |
Recombinant (E. coli) West Nile N-terminus Envelope Virus (WNV) (E. Coli, >95%, 42 Kda, his-tag) |
|||
RP-1456 | Alpha Diagnostics | 50 ug | EUR 343.2 |
Anti-West Nile Virus(WNV)(lineage 1, strain NY99) E/Envelope Polyclonal Antibody |
|||
E-AB-V1321-100uL | Elabscience Biotech | 100uL | EUR 415 |
Description: Unconjugated |
Anti-West Nile Virus(WNV)(lineage 1, strain NY99) E/Envelope Polyclonal Antibody |
|||
E-AB-V1321-50uL | Elabscience Biotech | 50uL | EUR 250 |
Description: Unconjugated |
Anti-West Nile Virus(WNV)(lineage 1, strain NY99) E/Envelope Polyclonal Antibody |
|||
E-AB-V1321-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
Anti-West Nile Virus(WNV)(lineage 1, strain NY99) E/Envelope Polyclonal Antibody |
|||
E-AB-V1322-100uL | Elabscience Biotech | 100uL | EUR 415 |
Description: Unconjugated |
Anti-West Nile Virus(WNV)(lineage 1, strain NY99) E/Envelope Polyclonal Antibody |
|||
E-AB-V1322-50uL | Elabscience Biotech | 50uL | EUR 250 |
Description: Unconjugated |
Anti-West Nile Virus(WNV)(lineage 1, strain NY99) E/Envelope Polyclonal Antibody |
|||
E-AB-V1322-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
Recombinant (E. coli) West Nile Virus Envelop (WNV-E) protein (>95%, ~42 Kda, His-tag) |
|||
WNVE15-R-50 | Alpha Diagnostics | 50 ug | EUR 343.2 |
Anti-West Nile Virus(WNV)(lineage 1, strain NY99) E/Envelope(Domain III) Monoclonal Antibody |
|||
E-AB-V1325-100uL | Elabscience Biotech | 100uL | EUR 415 |
Description: Unconjugated |
Anti-West Nile Virus(WNV)(lineage 1, strain NY99) E/Envelope(Domain III) Monoclonal Antibody |
|||
E-AB-V1325-50uL | Elabscience Biotech | 50uL | EUR 250 |
Description: Unconjugated |
Anti-West Nile Virus(WNV)(lineage 1, strain NY99) E/Envelope(Domain III) Monoclonal Antibody |
|||
E-AB-V1325-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
Recombinant (HEK) West Nile Virus Envelop (WNV-E, domain III) protein (>95%, ~12 Kda, His-tag) |
|||
WNVE16-R-50 | Alpha Diagnostics | 50 ug | EUR 489.6 |
Anti-West Nile Virus(WNV)(lineage 1, strain NY99) E/Envelope Protein(Domain III) Monoclonal Antibody |
|||
E-AB-V1323-100uL | Elabscience Biotech | 100uL | EUR 415 |
Description: Unconjugated |
Anti-West Nile Virus(WNV)(lineage 1, strain NY99) E/Envelope Protein(Domain III) Monoclonal Antibody |
|||
E-AB-V1323-50uL | Elabscience Biotech | 50uL | EUR 250 |
Description: Unconjugated |
Anti-West Nile Virus(WNV)(lineage 1, strain NY99) E/Envelope Protein(Domain III) Monoclonal Antibody |
|||
E-AB-V1323-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
Anti-West Nile Virus(WNV)(lineage 1, strain NY99) E/Envelope Protein(Domain III) Monoclonal Antibody |
|||
E-AB-V1324-100uL | Elabscience Biotech | 100uL | EUR 415 |
Description: Unconjugated |
Anti-West Nile Virus(WNV)(lineage 1, strain NY99) E/Envelope Protein(Domain III) Monoclonal Antibody |
|||
E-AB-V1324-50uL | Elabscience Biotech | 50uL | EUR 250 |
Description: Unconjugated |
Anti-West Nile Virus(WNV)(lineage 1, strain NY99) E/Envelope Protein(Domain III) Monoclonal Antibody |
|||
E-AB-V1324-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
Rabbit Anti-West Nile Virus (WNV) envelop protein antiserum |
|||
WNV16-S | Alpha Diagnostics | 100 ul | EUR 548.4 |
Recombinant (yeast) West Nile Virus Envelop (WNV-E, domain III, lineage 2) protein (>95%, ~12 Kda, His-tag) |
|||
WNVE17-R-50 | Alpha Diagnostics | 50 ug | EUR 489.6 |
West nile virus |
|||
Oneq-VH054-OneqVH054100R | Bioingentech | Oneq-VH054-100R | EUR 1028 |
West nile virus |
|||
Oneq-VH054-OneqVH054150R | Bioingentech | Oneq-VH054-150R | EUR 1438 |
West nile virus |
|||
Oneq-VH054-OneqVH05450R | Bioingentech | Oneq-VH054-50R | EUR 728 |
West nile virus |
|||
PCR-VH054-PCRVH05448R | Bioingentech | PCR-VH054-48R | EUR 485 |
West nile virus |
|||
PCR-VH054-PCRVH05496R | Bioingentech | PCR-VH054-96R | EUR 685 |
West Nile virus lysate |
|||
NAT41561-100 | The Native Antigen Company | 0.1 | EUR 512.85 |
Description: Purified West Nile virus Lysate (NY 2001-6263 strain). |
West Nile virus antibody |
|||
10-1436 | Fitzgerald | 100 ug | EUR 425 |
Description: Mouse monoclonal West Nile virus antibody |
West Nile virus antibody |
|||
10-1437 | Fitzgerald | 100 ug | EUR 425 |
Description: Mouse monoclonal West Nile virus antibody |
West Nile Virus Antibody |
|||
GWB-376E67 | GenWay Biotech | 0.1 mg | Ask for price |
West Nile Virus Antibody |
|||
GWB-4D0204 | GenWay Biotech | 0.1 mg | Ask for price |
West Nile Virus Antibody |
|||
GWB-B704DB | GenWay Biotech | 0.1 mg | Ask for price |
West Nile Virus Antibody |
|||
GWB-E45DB2 | GenWay Biotech | 0.1 mg | Ask for price |
West Nile Virus ENV recombinant antigen |
|||
00403-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: West Nile Virus Envelope full length recombinant antigen 42 kDa region |
West Nile Virus ENV recombinant antigen |
|||
00403-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: West Nile Virus Envelope full length recombinant antigen 42 kDa region |
Virus West Nile Virus (WNV) Protein |
|||
abx670276-100ug | Abbexa | 100 ug | EUR 794.4 |
West Nile Virus E Prot. |
|||
GWB-41C2BC | GenWay Biotech | 0.1 mg | Ask for price |
West Nile Virus (Pre-M) |
|||
GWB-C79A8B | GenWay Biotech | 0.1 mg | Ask for price |
West nile virus PCR kit |
|||
PCR-VH054-48R | Bioingentech | 50T | EUR 987.6 |
West nile virus PCR kit |
|||
PCR-VH054-96R | Bioingentech | 100T | EUR 1335.6 |
West Nile Virus Pre-MHis |
|||
PR-1274 | Jena Bioscience GmbH | 100µg | EUR 300.7 |
Description: recombinant, E. coli |
Mouse Anti-West Nile Virus Envelop Protein (WNV-E) IgG ELISA kit, 96 tests, Quantitative |
|||
910-280-WNG | Alpha Diagnostics | 1 Kit | EUR 1000.8 |
Mouse Anti-West Nile Virus Envelop Protein (WNV-E) IgM ELISA kit, 96 tests, Quantitative |
|||
910-285-WNM | Alpha Diagnostics | 1 Kit | EUR 1000.8 |
Human Anti-West Nile Virus Envelop Protein (WNV-E) IgG ELISA kit, 96 tests, Quantitative |
|||
910-380-WNG | Alpha Diagnostics | 1 Kit | EUR 1000.8 |
Human Anti-West Nile Virus Envelop Protein (WNV-E) IgM ELISA kit, 96 tests, Quantitative |
|||
910-385-WNM | Alpha Diagnostics | 1 Kit | EUR 1000.8 |
Monkey Anti-West Nile Virus Envelop Protein (WNV-E) IgG ELISA kit, 96 tests, Quantitative |
|||
910-480-WNG | Alpha Diagnostics | 1 Kit | EUR 1000.8 |
Monkey Anti-West Nile Virus Envelop Protein (WNV-E) IgM ELISA kit, 96 tests, Quantitative |
|||
910-485-WNM | Alpha Diagnostics | 1 Kit | EUR 1000.8 |
West Nile Virus NS1 protein |
|||
80-1546 | Fitzgerald | 100 ug | EUR 541.2 |
Description: Purified Recombinant West Nile Virus NS1 protein (His tag) |
West Nile Virus NS1 Protein |
|||
WNV-NS1-100 | The Native Antigen Company | 0.1 | EUR 318.94 |
Description: Recombinant West Nile Virus NS1 protein produced in 293 human cells. Protein contains a C-terminal His-tag. |
West Nile Virus NS1 Protein |
|||
WNV-NS1-500 | The Native Antigen Company | 0.5 | EUR 1305.1 |
Description: Recombinant West Nile Virus NS1 protein produced in 293 human cells. Protein contains a C-terminal His-tag. |
West Nile Virus (WNV) Protein |
|||
abx670276-50g | Abbexa | 50 µg | EUR 587.5 |
West Nile Virus Core Peptide |
|||
3435P | ProSci | 0.05 mg | EUR 197.7 |
Description: (CT) West Nile Virus Core peptide |
West Nile Virus (WNV) Antibody |
|||
abx412023-01mg | Abbexa | 0.1 mg | EUR 610.8 |
West Nile Virus NS3 Protease |
|||
GWB-904E07 | GenWay Biotech | 0.01 mg | Ask for price |
West Nile Virus (WNV) Antibody |
|||
abx412023-100g | Abbexa | 100 µg | EUR 537.5 |
×
Neural stem cells, neurons and mind organoids derived from the engineered hiPSCs proceed to precise the amber suppression equipment and produce ncAA-bearing reporter. The integrated ncAA can function a minimal bioorthogonal deal with for additional modifications by labeling with fluorescent dyes. Website-directed ncAA mutagenesis will open a variety of functions to probe and manipulate proteins in mind organoids and different hiPSC-derived cell varieties and complicated tissue fashions.
Tags: anti ki67 antibody labeling biotin lysine bl21 de3 cells bsa western blot dicer antibody empty chromatography column exosome isolation kit fetal bovine serum gk1 5 gli2 antibody human egf immunoprecipitation protocol magnetic beads kinase assay kit mouse igg isotype control mouse igg1 isotype control p40 antibody phalloidin 568 qpcr 96 well plate qubit dna concentration qubit hs rbc lysis buffer recipe renilla luciferase assay rt pcr kits satb2 antibody sirna transfection protocol streptavidin antibodies streptavidin magnetic beads superscript ii reverse transcriptase tbk1 antibody testosterone elisa traf6 antibody western blotting kits